cyrilzakka/clinical-trials huggingface dataset:
Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

The purpose of the study is to understand the effect of the dietary supplement "Nicotinamide mononucleotide" on metabolic health in people.

This study is is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease. Accordingly, the investigators will evaluate the effect of NMN on how well the hormone insulin works to control blood sugar. The investigators will also look at the effects of NMN on blood lipids; body fat and liver fat; and other blood, fat tissue and muscle tissue markers of cardiovascular (heart) and metabolic health. Data from studies conducted in rodents have shown that NMN supplementation has beneficial effects on cardiovascular and metabolic health, but this has not yet been studied in people.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal women 55-75 years old
* BMI 25.0-44.9 kg/m²
* Fasting plasma glucose concentration ≥100 mg/dl, OGTT 2 hour glucose ≥ 140 mg/dl, HbA1C ≥5.7%, or HOMA-IR ≥2.5

Exclusion Criteria:

* Diabetes
* Premenopausal or menopause \<1 year
* Persons who have received hormone replacement therapy within the past 6 months
* Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period.
* Structured exercise: ≥75 min/wk of vigorous exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥150 min/wk of low intensity physical activity (e.g., brisk walking).
* Unstable weight (\>3% change during the last 2 months before entering the study)
* Significant organ system dysfunction or disease
* Present cancer or history of cancer that has been in remission for \<5 years
* Polycystic ovary syndrome
* Major psychiatric illness
* Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study
* Metal implants
* Smokes cigarettes
* Persons who consume \>14 units of alcohol per week
* Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.
Initial Education for Rehabilitation and Motivation Program Following a Myocardial Infarction Via SMS or Hospital

The innovation in this preliminary study is the use of message reminders in patients after myocardial infarction in stage I of rehabilitation (ie discharge from hospital) at home via SMS, compared with studies of patients undergoing cardiac rehabilitation (stage II)in the hospital physiotherapy department.

The first stage of rehabilitation begins during hospitalization. Motivation for the rehabilitation process for the patient. At this stage there will be preparation for release and guidance for the patient and their families regarding secondary prevention and return to domestic activity. This stage includes mobility, walking, controlled motility and gradual joint activation to maintain ranges and prevent complications from prolonged immobilization in bed.

Eligibility Criteria:
Inclusion Criteria:

Informed consent Criteria for inclusion Patients after acute myocardial infarction admitted to the intensive care unit Patients who speak the Hebrew language Patients with a cell phone to receive a reminder using a message

Exclusion criteria:

Orthopedic or neurological problem that would prevent physical activity. A score lower than 24 in the MoCA test. High-risk patients.

Complications: of myocardial infarction congestive heart failure, cardiogenic shock and / or ventricular arrhythmias.

Angina or shortness of breath at rest. Decrease \>1mm in the ST segment in the ECG.
Less to Hold - A Comparison of Bladder Toxicities (Side Effects) in Patients Undergoing Prostate Radiotherapy Between Patients Treated With Empty Bladder and Those on a Drinking Protocol.

Radical radiotherapy to the prostate is conventionally treated with a full bladder with the aim of minimising dose to the bladder and small bowel to prevent significant side effects. Tolerance of the bladder filling protocol varies depending on patients' baseline urinary function. It is not uncommon for some men to have "accidents" during treatment causing understandable distress. This can also extend the treatment time and cause knock on delays in the radiotherapy department.

Several United Kingdom (UK) centres report treating with an empty bladder. The investigators carried out a feasibility study comparing treatment with full bladder to empty bladder to ascertain if the investigators can safely change our protocol to that of an empty bladder.

50 patients receiving radical radiotherapy to the prostate were randomised using closed envelope technique 1:1 into 2 groups. Group A followed the conventional drinking protocol at our centre (200ml prior to treatment) and group B were treated with an empty bladder. Baseline, end of treatment and 6 week follow up scores were prospectively collected for International prostate Symptom Score(IPSS), Late Effects Normal Tissue Task Force - Subjective, Objective, Management, Analytic (LENT SOMA) bowel toxicity and quality of life questionnaires. The investigators also looked at bowel and bladder Dose Volume Histogram (DVH) to ensure constraints were met.

Eligibility Criteria:
Inclusion Criteria:

* Prostate cancer receiving radical radiotherapy.

Exclusion Criteria:

* Not nodal disease.
* Not prostate bed radiotherapy.
Progressive Resistance Training in Patients With Class III Obesity

To test the strength and physical performance outcomes of a 12-week progressive resistance training (PRT) exercise program in a small cohort of patients with Class III obesity who are preparing for bariatric weight loss surgery at Beth Israel Deaconess. The study will also test patient compliance to the 12 week PRT program. Whereas PRT exercise is currently recommended as a part of preoperative clinical care for bariatric surgery patients, little research has been done to measure the acceptance and effectiveness of a standardized PRT exercise protocol for improving health and perioperative care. Preliminary data from this study could be used to justify larger studies and further investigation.


Eligibility Criteria:
Inclusion Criteria:

* Men and women 18-65 years old
* A BMI of ≥40 kg/m2
* Considering Weight Loss Surgery at BIDMC
* Participating in multidisciplinary preoperative program:

  * been determined by a mental health professional (i.e., psychologist or social worker) to be well-informed, motivated, and not symptomatic for psychopathology that would put the person at risk for injury or failure with WLS
  * expressed strong desire for significant weight loss
  * experienced documented failure of long-term weight loss using nonsurgical methods
  * been informed of and accepts risks of surgery
* Cleared by their primary care physician to be in stable health and capable of moderate level exercise
* Willing to comply with expected attendance and participation at all intervention sessions and testing appointments
* Has reliable transportation to the intervention location

Exclusion Criteria:

* Orthopedic limitations that would preclude exercise testing and training
PreView: The Preventive Video Education in Waiting Rooms Program

This clinical trial studies how well PreView, preventive video education, works in increasing rates of breast, cervical and colorectal cancer screening, improving participants' stage of change with respect to age appropriate cancer screening and increasing patient-provider discussions about prostate cancer screening.

PRIMARY OBJECTIVES:

I. To determine the extent to which PreView increases the likelihood that primary care patient participants will receive mammograms, pap tests, colon cancer tests or prostate specific antigen (PSA) testing discussions with primary care physicians compared with participants who receive usual care.

II. To determine the extent that PreView increases participants' readiness to be screened for breast cancer, cervical cancer or colorectal cancer (CRC) compared with usual care.

III. To determine the extent that PreView increases the likelihood that PSA testing will be discussed in primary care physician visits compared with usual care.

OUTLINE: Patients are randomized into 1 of 2 groups.

GROUP I: Patients complete PreView, the Video Doctor plus Provider Alert, over 45 minutes on an iPad in the waiting room before a doctor visit.

GROUP II: Patients watch a video about healthy lifestyles including information about exercise and healthy eating over 45 minutes on an iPad in the waiting room before a doctor visit.

Eligibility Criteria:
Inclusion Criteria:

* Without a history of cancer

Exclusion Criteria:

* With a history of cancer (for whom subsequent procedures would be surveillance and not screening)
* Individuals who do not speak English or Spanish (except for the testimonials)
Endovascular Graft Anchoring Different Regions of Ascending Aorta in the Treatment of Ascending Aortic Dissection

Aortic dissection is a deadly and dangerous disease. About 28% of patients with ascending aortic dissection can't tolerate open surgical trauma caused by thoracotomy and cardiopulmonary bypass, and the prognosis is poor. Minimally invasive endovascular treatment has been applied in the treatment of descending aortic dissection. However, due to the special anatomical structure and high speed /pressure blood flow, the treatment of ascending aorta dissection has become an international difficulty.

This study was designed combination of retrospective and prospective methods, and focused on distal false lumen Aneurysmal Expansion of Aortic Dissection (DAEAD) . To formulate clinical data for the risk assessment of DAEAD, and best intracavitary treatment or long-term efficacy evaluation, we combined the results of genetic testing, evaluating the missense mutation, computer simulation of blood flow dynamics analysis, and clinical imaging analysis.

Eligibility Criteria:
Inclusion Criteria:

* Aortic dissection diagnosed by CTA;
* With indications for endovascular treatment
* The luminal graft anchor is required to be located in the ascending aorta.

Exclusion Criteria:

* Import difficult, such as external iliac artery diameter is less than 6 mm bilateral iliac, artery stenosis distortions;
* Patients with severe comorbidities, such as severe myocardial insufficient blood supply, heart failure, arrhythmia, severe renal dysfunction, and severe blood coagulation dysfunction;
* Patients with malignant tumor, or other serious illness, life expectancy of less than 1 year；
* Puncture local infection and high fever;⑤ within 1 month of the large area;
* Contrast media in patients with cerebrovascular accident or digestive tract hemorrhage patients with allergies;
* Aortic ulcer or aortic wall hematoma and other atypical dissection.
3D Autotransplantation of Teeth

The study aims to clarify the usefulness of 3D-printed replicas in association with autotransplantation of teeth in children and young adults.


Eligibility Criteria:
Inclusion Criteria:

* Need for tooth transplantation
* Open apex tooth available for transplantation

Exclusion Criteria:

* Facial syndrome
* Chronic facial pain
* Allergy to replica material
Self-Help Video for Insomnia in College Students

The purpose of this study is to test the effectiveness of a 1-session abbreviated cognitive-behavior therapy for insomnia among college students. The investigators will examine the following hypotheses in the present study: 1) Viewing the treatment video will produce an increment in sleep knowledge relative to baseline and minimum treatment control; and 2) Viewing the treatment video will result in improved sleep relative to baseline and minimum treatment control.

Students who self-identify as having insomnia will be recruited from the University of Alabama's Psychology subject pool. Students who enroll in the study will receive a link to the demographic and screening questionnaire. Individuals who have a history of other sleep disorders or who currently present with symptoms strongly suggestive of sleep disorders, such as obstructive sleep apnea or narcolepsy will be excluded. Individuals who are shift-workers and those with a history of severe mental illness will also be excluded.

Participants who meet criteria for this study will then be directed to complete a measure of sleep knowledge. Once they have completed the measure of sleep knowledge, they will be directed to complete the Consensus Sleep Diary (CSD) for 14 days as soon as possible after awakening in the morning. During the second week of completing the CSD, participants will be directed to complete the Insomnia Severity Index and the Patient-Reported Outcomes Measurement Information System Sleep Disturbance and Sleep-Related Impairments Short Forms on the last day they complete a CSD.

Participants will be randomized to a treatment group or a minimum treatment control group upon completion of these baseline measures. Those in the treatment group will be emailed the following components of the insomnia treatment: a link to the treatment video, an mp3 file with a relaxation recording, and a pdf file of a brochure reviewing the information presented in the treatment video. Participants will be asked to view the treatment video and begin practicing the relaxation technique presented in the mp3 file as soon as possible. Participants in the minimum treatment control group will receive a link to a sleep education video.

Two weeks after participants have viewed the videos, they will be asked to complete post-treatment measures in the same sequence as they did at baseline. One month after the post-treatment measures have been completed, both groups will be asked to complete the same measures again for follow-up.


Eligibility Criteria:
Inclusion Criteria:

* Must be a student at The University of Alabama
* Must be 18-24 years old
* Must have a complaint of insomnia

Exclusion Criteria:

* history of sleep disorder other than insomnia
* symptoms strongly suggestive of sleep disorders other than insomnia
* shift-work
* history of severe mental illness (e.g., psychotic disorders, bipolar disorder, severe depression, or personality disorders)
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.


Eligibility Criteria:
Inclusion Criteria:

Planned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant

Exclusion Criteria:

Participation in any other treatment research protocol
Value of Urodynamics Prior to Stress Incontinence Surgery 2

To test the value of preoperatively performed urodynamics with regard to outcome of surgery for stress urinary incontinence (SUI) and to examine whether not performing urodynamics preoperatively is more cost effective than performing urodynamics preoperatively using the non-inferiority assumption.


Eligibility Criteria:
Inclusion Criteria:

* Symptoms of stress urinary incontinence and/or mixed urinary incontinence, predominantly stress incontinence
* Signs of stress urinary incontinence on physical examination or voiding-diary
* Patient is a candidate for surgical treatment (as based on history and physical examination)
* Patient has attended at least 3 months of physiotherapy
* Patient accepts randomisation
* Patient is capable to fill out bladder diary's, pad tests and questionnaires
* Patient understands the Dutch written and spoken language
* ASA 1 or 2

Exclusion Criteria:

* Previous incontinence surgery
* Mixed urinary incontinence, urge component is predominant
* Prolapse \>= 1cm beyond the hymen on Valsalva in supine position
* Postvoid urinary residual \> 150ml
* Present urinary tract infection
* The need for additional pelvic surgery (prolapse and/or hysterectomy)
* Patient is or wants to become pregnant
* Prior pelvic radiotherapy
Propranolol Rescue of Prolonged Labor

A double-blind placebo controlled randomized trial comparing cesarean delivery rates in women given IV propranolol versus placebo for treatment of prolonged labor.

A double-blind placebo controlled randomized trial comparing cesarean delivery rates in 326 women given IV propranolol (2 mg with one possible repeat dose greater than 2 hours later) versus IV placebo for treatment of prolonged labor.

Eligibility Criteria:
Inclusion Criteria:

English-speaking

\>= 36 weeks gestation

Singleton pregnancy

Vertex presentation

No contraindication to a vaginal delivery

Meets at least one study criteria for prolonged labor:

1. cervical dilation \<6 cm after ≥8 hours with ruptured membranes and receiving oxytocin OR
2. cervical dilation \>=6 cm and \<1 cm dilation change over ≥2 hours with ruptured membranes and receiving oxytocin

Exclusion Criteria:

Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for hypertension control

Receiving other beta blocker

Maternal heart rate \< 70 beats per minute, systolic blood pressure \<90 mmHg, or diastolic blood pressure \<50 mmHg on two sets of vital signs in the 1 hour prior to study drug administration: given that bradycardia and hypotension are possible side effects of propranolol

History of any form of asthma: as this is a contraindication to beta blocker use

Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in the neonate

Any cardiac condition for which β blockade is contraindicated (cardiogenic shock, sinus bradycardia, and greater than first degree heart block)

Known hypersensitivity to propranolol

Intrauterine fetal demise since different labor protocols are used in these women

Major fetal congenital anomaly since rate of cesarean may be inherently different in these women, unrelated to labor
Intervention With Cerebral Embolic Protection in TEVAR: Gaseous Protection

Vascular brain infarction (VBI) occurs in 67% of patients undergoing TEVAR. Overt stroke occurs in 13% of these patients and 88% of patients suffer from neurocognitive impairment.

Cerebral air embolisation during the stent-graft deployment phase of TEVAR may be a cause of VBI. Standard treatment to de-air stent-grafts is through the use of a saline flush.

This study aims to investigate whether carbon-dioxide or saline is the better fluid to de-air TEVAR stent-grafts prior to insertion in to the patient and compare VBI rate in the carbon-dioxide group and saline group.

Thoracic endovascular aortic repair (TEVAR) is the re-lining of the thoracic aorta to prevent life threatening haemorrhage and death from rupture. This involves a small cut in the femoral artery in the groin and under imaging guidance, the insertion of wires and a stent into the thoracic aorta.

Prior to insertion into the patient, stents are flushed with saline to remove air and prevent air reaching the brain that can cause a form of brain injury known as vascular brain infarction (VBI). However, our preliminary clinical data suggests that saline flushing is not effective at de-airing stent-grafts used in TEVAR.

Carbon-dioxide has been used extensively in cardiac surgery to displace air from the chest cavity to prevent peri-procedural cerebral air embolisation. We hypothesise that flushing the stent-grafts with carbon-dioxide may be better at removing air from the stent-grafts than saline flush.

Patients undergoing TEVAR will be approached to participate in this study. After written consent is obtained, participants will be randomised to undergo (TEVAR) with carbon dioxide or saline flushing of stent-grafts. Pre-operatively, participants will undergo extensive neurocognitive testing, and a baseline blood test. Intra-operatively, participants will undergo continuous transcranial doppler monitoring (TCD) of the middle cerebral artery (MCA) to look for cerebral air embolisation at stent-graft deployment phase of TEVAR. Blood testing pre-op, immediately post op, and 24 hours post op will be taken to measure for biomarkers of brain injury. Post-operatively, participants will undergo another diffusion-weighted brain MRI within 72 hours post-procedure, stroke and delirium assessment at day 1, 3 and day 7 +/- day of discharge, and at 6-weeks and 6-month follow-up.

Eligibility Criteria:
Inclusion Criteria:

* All participants suitable for TEVAR with capacity to consent

Exclusion Criteria:

* Participants who lack capacity to consent
* Contraindications to MRI such as pacemaker
* Pregnant participants
* Participants who do not wish to participate
* Participants \<18yrs
H5N1 Milk Detection Study

The purpose of this study is to determine whether drinking pasteurized milk (milk heated to kill harmful germs) that contains inactive particles of a flu virus called A(H5) could lead to the detection of the virus in the nose or throat. Inactive particles are not capable of causing disease. The results will help the Centers for Disease Control and Prevention (CDC) better understand how milk consumption could affect flu surveillance. Investigators also want to see if the body produces antibodies in response to this milk consumption.

Since March 2024, avian influenza A (H5N1) viruses have infected U.S. dairy cattle and spread widely. The virus has been identified in high concentrations in raw milk, and research shows that pasteurization - the process of heating milk to a specific temperature for a set time - inactivates the A (H5N1) virus. Therefore, the Food and Drug Administration (FDA) says that commercial pasteurized milk is safe for consumption. However, trace amounts of inactive influenza particles may still be detected in pasteurized milk.

This study aims to determine whether drinking pasteurized milk could be a possible exposure for H5N1 influenza detection. The findings will support the Centers for Disease Control and Prevention's (CDC) efforts to evaluate milk consumption as a factor in influenza surveillance and provide context for interpreting surveillance data.

Healthy adults will drink 250 mL of pasteurized milk containing the inactive H5N1 virus, provided by the CDC, either during a single visit or over three consecutive daily visits. Nasal and combined nasal/oral swabs will be collected immediately following milk consumption to assess the presence of influenza. Additionally, a subset of participants will provide blood, saliva, and stool samples at the initial visit and again 21-30 days post-consumption.

Eligibility Criteria:
Inclusion Criteria:

* Individuals aged 18-64 years
* BMI ≤ 35 kg/m2
* Able to understand and give informed consent (American English) and comply with study visits and procedures.
* In good general health based on medical history and the investigator's clinical judgment.

Exclusion Criteria:

* Symptoms of acute respiratory illness or conjunctivitis within 7 days
* Febrile illness in the previous 72 hours
* Recent influenza antiviral use (within 14 days)
* Immunosuppression due to illness or medications
* Current pregnancy or breastfeeding
* History of allergy or intolerance to milk or milk alternatives
* Consumption of raw (unpasteurized) milk within the previous 14 days
* Recent work (within 14 days) on a farm with animals known to be infected with A(H5) virus
* Previous receipt of A(H5) vaccine at any time